Brilliant Violet 421(TM) anti-human CD4 317433 from BioLegend

Product Specs
ItemBrilliant Violet 421(TM) anti-human CD4
CompanyBioLegend
Price Pricing Info Supplier Page View Company Product Page
Catalog Number317433
Conjugate/TagBrilliant Violet 421™
Quantity25 tests
IsotypeIgG2b, Kappa
NCBI Gene AliasesCD4mut, IMD79, Leu-3, OKT4D, T4
ApplicationsFlow Cytometry (FC), Immunocytochemistry (ICC)
ReactivityHuman, Cynomolgus, Rhesus
HostMouse
CloneOKT4
Antibody TypePrimary
NCBI Full Gene NameCD4 molecule
FormatPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
ClonalityMonoclonal
ImmunogenHuman peripheral T cells
TargetCD4

Add to Compare List

BioLegend

8999 BioLegend Way

San Diego, California 92121

United States

Phone: 1-877-246-5343 Toll-Free, USA & Canada
1-858-768-5800 International
Fax: 1-877-455-9587

Company Profile

Website: biolegend.com

(1) Complement activation induces excessive T cell cytotoxicity in severe COVID-19CellFebruary 3, 2022Georg P, Astaburuaga-García R, Bonaguro L, Brumhard S, Michalick L, Lippert LJ, Kostevc T, Gäbel C, Schneider M, Streitz M, et al.

(2) Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaquesCellJanuary 21, 2021Hoang TN, Pino M, Boddapati AK, Viox EG, Starke CE, Upadhyay AA, Gumber S, Nekorchuk M, Busman-Sahay K, Strongin Z, et al.

(3) Liver Immune Profiling Reveals Pathogenesis and Therapeutics for Biliary AtresiaCellDecember 23, 2020Wang J, Xu Y, Chen Z, Liang J, Lin Z, Liang H, Xu Y, Wu Q, Guo X, Nie J, et al.

(4) Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell SignatureCell reportsAugust 4, 2020Cheng C, Duan H, Xu K, Chuang GY, Corrigan AR, Geng H, O'Dell S, Ou L, Chambers M, Changela A, et al.

(5) Intratumoral CD4⁺ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder CancerCellJune 25, 2020Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, et al.

(6) Oncolytic virus-derived type I interferon restricts CAR T cell therapyNature communicationsJune 24, 2020Evgin L, Huff AL, Wongthida P, Thompson J, Kottke T, Tonne J, Schuelke M, Ayasoufi K, Driscoll CB, Shim KG, et al.fluorochrome-conjugated antibodies against combinations of the following antigens: CD4 (Biolegend # 317433, clone OKT4, dilution 1:250), CD8 (Biolegend #300914, clone HIT8a, dilution 1:250), PD1 (Biolegend #329923,

(7) C/EBPα and GATA-2 Mutations Induce Bilineage Acute Erythroid Leukemia through Transformation of a Neomorphic Neutrophil-Erythroid ProgenitorCancer cellMay 11, 2020Di Genua C, Valletta S, Buono M, Stoilova B, Sweeney C, Rodriguez-Meira A, Grover A, Drissen R, Meng Y, Beveridge R, et al.BV421,BioLegend,"Clone OKT3, Cat#317343;RRID: AB_2565848" Anti-human CD4 BV421,BioLegend,"Clone OKT4, Cat#317433;RRID: AB_11150413" Anti-human CD8a BV421,BioLegend,"Clone RPA-T8, Cat#301035;RRID: AB_10898322" Anti-human

(8) CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic MalignanciesMolecular therapy : the journal of the American Society of Gene TherapyFebruary 5, 2020Rodriguez-Garcia A, Sharma P, Poussin M, Boesteanu AC, Minutolo NG, Gitto SB, Omran DK, Robinson MK, Adams GP, Simpkins F, et al.

(9) A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in AustraliaDrug design, development and therapyJanuary 1, 2020Lickliter JD, Gan HK, Voskoboynik M, Arulananda S, Gao B, Nagrial A, Grimison P, Harrison M, Zou J, Zhang L, et al.

(10) Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8⁺ T CellsCancer cellDecember 9, 2019Etxeberria I, Bolaños E, Quetglas JI, Gros A, Villanueva A, Palomero J, Sánchez-Paulete AR, Piulats JM, Matias-Guiu X, Olivera I, et al.

(11) Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV NeutralizationCellJuly 25, 2019Kong R, Duan H, Sheng Z, Xu K, Acharya P, Chen X, Cheng C, Dingens AS, Gorman J, Sastry M, et al.,ThermoFisher Scientific,Cat# L34955 Anti-human CD3 BV421,BD PharMingen,Cat# 562877 Anti-human CD4 BV421,BioLegend,Cat# 317433 Anti-human CD8 BV421,Biolegend,Cat# 301036 Anti-human CD14 BV421,BioLegend,Cat# 301829 Anti-human

(12) Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune CompatibilityCell stem cellApril 4, 2019Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N, Ueda T, Gee P, Nishikawa M, Nomura M, et al.

(13) Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cellsJCI insightMarch 21, 2019Dawson NA, Lamarche C, Hoeppli RE, Bergqvist P, Fung VC, McIver E, Huang Q, Gillies J, Speck M, Orban PC, et al.

(14) Functional proteomic atlas of HIV infection in primary human CD4+ T cellseLifeMarch 12, 2019Naamati A, Williamson JC, Greenwood EJ, Marelli S, Lehner PJ, Matheson NJ.

(15) Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicansCellMarch 7, 2019Bacher P, Hohnstein T, Beerbaum E, Röcker M, Blango MG, Kaufmann S, Röhmel J, Eschenhagen P, Grehn C, Seidel K, et al.

(16) Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human MelanomaCellFebruary 7, 2019Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi ACJ, van den Braber M, Rozeman EA, Haanen JBAG, Blank CU, et al.

(17) Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer ImmunotherapyCell stem cellDecember 6, 2018Minagawa A, Yoshikawa T, Yasukawa M, Hotta A, Kunitomo M, Iriguchi S, Takiguchi M, Kassai Y, Imai E, Yasui Y, et al.

(18) Peptidylarginine deiminases 2 and 4 modulate innate and adaptive immune responses in TLR-7-dependent lupusJCI insightDecember 6, 2018Liu Y, Lightfoot YL, Seto N, Carmona-Rivera C, Moore E, Goel R, O'Neil L, Mistry P, Hoffmann V, Mondal S, et al.

(19) Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free MediumMolecular therapy. Methods & clinical developmentMarch 16, 2018Medvec AR, Ecker C, Kong H, Winters EA, Glover J, Varela-Rohena A, Riley JL.a ratio of 2:1 and incubated for 5 hr with GolgiStop (BD Biosciences). Surface CD4 (BioLegend Cat# 317433) and CD8 (BD Biosciences Cat# 560273) staining was performed, samples were fixed, and the following

(20) The Xenobiotic Transporter Mdr1 Enforces T Cell Homeostasis in the Presence of Intestinal Bile AcidsImmunityDecember 19, 2017Cao W, Kayama H, Chen ML, Delmas A, Sun A, Kim SY, Rangarajan ES, McKevitt K, Beck AP, Jackson CB, et al.anti-human CD3, Clone OKT3",BioLegend,Cat# 317321 "BV421 anti-human CD4, Clone OKT4",BioLegend,Cat# 317433 "PE-Cy7 anti-human CD45RO, Clone UCHL1",BioLegend,Cat# 304229 "Percp-Cy5.5 anti-human CCR7, Clone

Write a Review

(1)

2/28/2017Staining T Cells With Anti-CD4 BV421 Adam GuessThis antibody was used to distinguish CD4+ T cells from CD8+ T cells. It was chosen because it is a commonly used clone for CD4, BV421 is bright and works well with other fluorophores in the staining ... Read Review

Brilliant Violet 421(TM) anti-human CD4 from BioLegend

Description

BioLegend

Citations (36)

Reviews

Brilliant Violet 421(TM) anti-human CD4 from BioLegend

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map